Trial Profile

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idecabtagene vicleucel (Primary) ; Carfilzomib; Cyclophosphamide; Fludarabine; Lenalidomide
Indications Multiple myeloma
Focus Adverse reactions
Acronyms KarMMa-4
Sponsors Celgene Corporation

Most Recent Events

21 Aug 2023 Status changed from active, no longer recruiting to completed.
23 Mar 2022 Planned End Date changed from 15 Jan 2025 to 14 Dec 2023.
23 Mar 2022 Planned primary completion date changed from 15 Jan 2025 to 14 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com